المؤلفون: Smith, Steven J.¹ (AUTHOR) smithsj2@mail.nih.gov, Zhao, Xue Zhi¹ (AUTHOR) burkete@nih.gov, Hughes, Stephen H.² (AUTHOR) hughesst@mail.nih.gov, Burke Jr., Terrence R.¹ (AUTHOR)

المصدر: Viruses (1999-4915). Jan2025, Vol. 17 Issue 1, p121. 10p.

مصطلحات موضوعية: *COVID-19 pandemic, *DOLUTEGRAVIR, *HIV, *COMPARATIVE studies, *INFECTION

المؤلفون: Yan, Dong¹ (AUTHOR), Hou, Xixi² (AUTHOR), Wu, Ziyuan¹ (AUTHOR), Wang, Xinyan¹ (AUTHOR), Hao, Xueqin¹ (AUTHOR) haoxueqin@haust.edu.cn, Wang, Lan¹ (AUTHOR), Mao, Longfei¹ (AUTHOR) longfeimao2022@163.com

المصدر: Russian Journal of Organic Chemistry. 2024 Suppl 1, Vol. 60, pS160-S170. 11p.

مصطلحات موضوعية: *HIV integrase inhibitors, *DOLUTEGRAVIR, *ORGANIC chemistry, *COST effectiveness, *ORGANIC compounds

المصدر: A Phase 2 Randomized Cross-Over Design Study of the Early Metabolic Effects of Dolutegravir or Tenofovir Alafenamide in Healthy Volunteers
Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016 Sep;3(9):e410-e420. doi: 10.1016/S2352-3018(16)30016-9. Epub 2016 May 27.
Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, Kulagin V, Givens N, de Oliveira CF, Brennan C; FLAMINGO study team. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015 Apr;2(4):e127-36. doi: 10.1016/S2352-3018(15)00027-2. Epub 2015 Mar 10. Erratum In: Lancet HIV. 2015 Apr;2(4):e126.
Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum In: Ann Intern Med. 2014 Nov 4;161(9):680.

المؤلفون: ViiV Healthcare, Mylan Inc.

المصدر: Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis

المؤلفون: ViiV Healthcare, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)

المصدر: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

Other URLs: http://www.impaactnetwork.org/

المساهمون: José Antonio Mata Marín, Principal Investigator

المصدر: Effect of Dolutegravir + Tenofovir Disoproxil Fumarato/Emtricitabina Compared with Darunavir/Cobicistat + Tenofovir Disoproxil/Fumarato /Emtricitabina on the Severity of Neuropsychiatric Effects Al 12 Weeks in Antirretroviral Treatment-Naive Adults with HIV-1 Infection

المصدر: Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Studies P1093 and P2019

Other URLs: https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

المؤلفون: Organization providing support funding (ANRS-MIE), Organization providing support methodology coordination (IPLESP)

المصدر: MODULO Trial: Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully Treated With Three-drug Regimens at Inclusion

المؤلفون: ViiV Healthcare

المصدر: Dolutegravir Plus Lamivudine (DTG/3TC) Dual Therapy Versus Dolutegravir With TDF-lamivudine (DTG + TDF/3TC) Among Antiretroviral naïve People With HIV and TB Receiving Rifampin-based TB Treatment

المصدر: Body Composition Sub-study of the D2EFT Trial

المؤلفون: Instituto Nacional de Saúde, Mozambique, Muhimbili University of Health and Allied Sciences, SolidarMed Lesotho, London School of Hygiene and Tropical Medicine

المساهمون: Loice Achieng Ombajo, Chief Investigator

المصدر: Investigating the Optimal Management of Dolutegravir Resistance: an Open-label Randomised Controlled Trial of Maintaining Dolutegravir or Switch to Ritonavir-boosted Darunavir

المؤلفون: Institut National de la Santé Et de la Recherche Médicale, France

المصدر: Phase III Multicenter Randomized Trial Evaluating in Patients At the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/emtricitabine and Dolutegravir or Tenofovir/emtricitabine and Darunavir/cobicistat

المؤلفون: APIN Public Health Initiatives, University of Cape Town

المساهمون: Holly Rawizza, M.D., M.P.H., Assistant Professor of Medicine

المصدر: Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

المصدر: 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

المؤلفون: Maasstad Hospital, Haaglanden Medical Centre, Catharina Ziekenhuis Eindhoven, Elisabeth-TweeSteden Ziekenhuis, Rijnstate Hospital, Admiraal de Ruyter Hospital, Spaarne Gasthuis, Medisch Spectrum Twente

المساهمون: Casper Rokx, MD PhD

المصدر: Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study.

المصدر: An Open Label, Comparative, Randomized , Phase IV Pilot Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

المؤلفون: Liverpool School of Tropical Medicine, Desmond Tutu Health Foundation

المصدر: Doravirine Dose Optimisation in Pregnancy

المؤلفون: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland, University of Bern

المصدر: Booster-free Antiretroviral Therapy for Persons Living With HIV and Multidrug Resistance: A Multicentre Multi-stage Randomized Trial

المصدر: Open Label Rollover Study of Triumeq in Patients with Amyotrophic Lateral Sclerosis (ALS) Following the Lighthouse II Trial

المؤلفون: Janssen Research & Development, LLC

المصدر: Phase 1/2 Study of Switching to Fixed Dose Combination Dolutegravir/Rilpivirine Among Virologically Suppressed Children, 6 to Less Than 12 Years of Age, Living With HIV-1

Other URLs: https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf